UNSPSC 51422117: Fluocortolone acetate

This classification denotes a therapeutic glucocorticoid C24H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0KV2P7H3C, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6-fluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as fluocortolone acetate, which bears US NIH Compound Identifier 22798516. European Medicines Agency schedules Fluocortolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02217MIG.

Most nations, for tariff and trade purposes, schedule fluocortolone acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTOLONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@H]1C(=O)COC(=O)C)C)O)C)F.

UNSPSC 51422117 Fluocortolone acetate is a Commodity code nominally describing a specific topical corticosteroid pharmaceutical, but recent state and local opportunities tagged under this code do not align with the code's stated scope. The most recent solicitations—Seminole County, Florida's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs—involve opioid antagonists, pharmaceutical distribution models, and pharmacy benefit administration rather than fluocortolone acetate or related dermatological products. This divergence suggests either miscoding in the jurisdictional procurement systems or a data-classification mismatch rather than active state and local demand for fluocortolone acetate specifically.

The issuing bodies pursuing opportunities under this code span county health departments and state health agencies. Seminole County released an IFB (Invitation for Bid) on June 30, 2026, with a response deadline of July 26, 2023, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and a two-year initial term with one-year renewal option. Texas Health and Human Services Commission issued an RFI (Request for Information) on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription fulfillment models for a Therapeutic Pharmacy Initiative program. The geographic activity appears limited to Florida and Texas in the recent record, though the small sample size and code-scope mismatch limit confidence in characterizing broader state-local demand for fluocortolone acetate itself.